Z17.31
Human epidermal growth factor receptor 2 positive status
Clinical Classification Guidelines
Inclusion Terms
- HER2+
Medical Intelligence & Overview
HER2-positive status refers to a specific characteristic of some cancer cells, predominantly found in breast cancer. This condition indicates an overexpression of the human epidermal growth factor receptor 2 (HER2) protein on the surface of the cells. Identifying HER2-positive tumors is essential because it influences treatment decisions and prognosis. The ICD-10 code Z17.31 is used for medical documentation when a patient’s tumor tests positive for HER2.
Causes & Symptoms
Clinical Causes: Genetic mutations that lead to increased production of HER2 protein Inheritance of gene mutations that predispose to HER2 overexpression Certain environmental factors that may influence gene expression (though less direct)
Key Symptoms: Lump or thickening in the breast or other affected area Changes in the size, shape, or appearance of the breast or abnormal swelling Skin changes over the breast, such as redness or puckering Nipple changes, including inversion or discharge Persistent pain or discomfort in the affected region
Diagnostic & Treatment
Diagnosis Path: Diagnosing HER2-positive status involves several laboratory tests on tumor tissue, including:
Treatment Protocols: Treatment strategies for HER2-positive cancers typically include:
Clinical Advice & FAQs
Billing Guidance
Is Z17.31 a billable ICD-10 code?
Yes, Z17.31 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z17.31?
Clinical documentation must specify the nature of Human epidermal growth factor receptor 2 positive status and any associated comorbidities for accurate reporting.
Cite this Clinical Reference